Sachin Jain, MD, MBA, FACP, president and CEO at SCAN Group and SCAN Health Plan, discusses how data can help ensure that vulnerable populations aren't harmed by value-based payment models.
Sachin Jain, MD, MBA, FACP, is the president and CEO at SCAN Group and SCAN Health Plan.
Transcript:
The paper you co-authored discussed the need to ensure that value-based payment models do not create incentives that work against vulnerable populations. How can data help overcome this problem?
Jain: Yeah. Ultimately, at the foundation of this concern is risk adjustment. I think there's always an unintended consequence when you introduce a payment model that rewards organizations for managing health care utilization, there's always a risk that organizations will selectively apply those payment models to certain populations, unless, of course, they're rewarded for actually taking on that higher degree of complexity. Of course, it's very hard to identify that complexity, oftentimes, when we don't actually have the data that you need to have to appropriately risk adjust or identify cohorts of populations that could benefit from more intensive services and that warrant higher levels of reimbursement. With a better core of data, there's opportunities to, I think, create a higher degree of specificity around who actually exists within a population, and then pay organizations accordingly.
I think one of the areas where we've seen real challenges with this is actually the Medicare Advantage star rating system, where you're rewarded for completing a number of preventative screenings on patients as well as providing certain patient experience levels. Ultimately, some populations are harder to serve than others, but there's not a lot of adjustment for that in the formulas that calculate those star ratings. So, while the star ratings are directionally fantastic and are appropriate, they introduce this challenge of potentially rewarding organizations for actually serving healthier populations. Again, I think we have an opportunity to do better and a better core of data could actually help us do that.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More